New drug combo tested for Tough-to-Treat blood cancers
NCT ID NCT04425070
Summary
This study tested whether adding a drug called selinexor to standard chemotherapy or an immunotherapy drug (tislelizumab) could help control advanced T-cell and NK-cell lymphomas that had returned or stopped responding to prior treatments. It involved adults whose cancer had come back after at least one prior treatment regimen. The main goals were to see if the combinations were safe and if they could shrink the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Cancer Hospital
Hefei, Anhui, 230031, China
-
Beijing Tongren Hospital.CMU
Beijing, Beijing Municipality, 100005, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, 210000, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
Tianjin Medical Universisity Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.